|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SPIRE1 |
Gene summary for SPIRE1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SPIRE1 | Gene ID | 56907 |
| Gene name | spire type actin nucleation factor 1 | |
| Gene Alias | Spir-1 | |
| Cytomap | 18p11.21 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q08AE8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56907 | SPIRE1 | P2T-E | Human | Esophagus | ESCC | 1.10e-09 | 1.71e-01 | 0.1177 |
| 56907 | SPIRE1 | P5T-E | Human | Esophagus | ESCC | 4.18e-03 | 8.16e-02 | 0.1327 |
| 56907 | SPIRE1 | P9T-E | Human | Esophagus | ESCC | 2.10e-03 | 8.62e-02 | 0.1131 |
| 56907 | SPIRE1 | P11T-E | Human | Esophagus | ESCC | 2.88e-05 | 1.94e-01 | 0.1426 |
| 56907 | SPIRE1 | P12T-E | Human | Esophagus | ESCC | 1.83e-07 | 1.06e-01 | 0.1122 |
| 56907 | SPIRE1 | P16T-E | Human | Esophagus | ESCC | 1.82e-05 | 1.33e-01 | 0.1153 |
| 56907 | SPIRE1 | P20T-E | Human | Esophagus | ESCC | 5.17e-07 | 1.67e-01 | 0.1124 |
| 56907 | SPIRE1 | P21T-E | Human | Esophagus | ESCC | 1.27e-03 | 1.20e-01 | 0.1617 |
| 56907 | SPIRE1 | P22T-E | Human | Esophagus | ESCC | 1.42e-05 | 9.07e-02 | 0.1236 |
| 56907 | SPIRE1 | P23T-E | Human | Esophagus | ESCC | 7.09e-04 | 9.75e-02 | 0.108 |
| 56907 | SPIRE1 | P24T-E | Human | Esophagus | ESCC | 1.21e-04 | 8.74e-02 | 0.1287 |
| 56907 | SPIRE1 | P26T-E | Human | Esophagus | ESCC | 3.28e-05 | 1.54e-01 | 0.1276 |
| 56907 | SPIRE1 | P28T-E | Human | Esophagus | ESCC | 3.25e-16 | 2.35e-01 | 0.1149 |
| 56907 | SPIRE1 | P31T-E | Human | Esophagus | ESCC | 4.68e-10 | 2.99e-01 | 0.1251 |
| 56907 | SPIRE1 | P32T-E | Human | Esophagus | ESCC | 3.34e-11 | 2.29e-01 | 0.1666 |
| 56907 | SPIRE1 | P36T-E | Human | Esophagus | ESCC | 3.78e-03 | 2.82e-01 | 0.1187 |
| 56907 | SPIRE1 | P37T-E | Human | Esophagus | ESCC | 5.59e-10 | 2.14e-01 | 0.1371 |
| 56907 | SPIRE1 | P38T-E | Human | Esophagus | ESCC | 7.68e-10 | 5.73e-01 | 0.127 |
| 56907 | SPIRE1 | P40T-E | Human | Esophagus | ESCC | 3.22e-06 | 1.84e-01 | 0.109 |
| 56907 | SPIRE1 | P42T-E | Human | Esophagus | ESCC | 5.63e-07 | 1.23e-01 | 0.1175 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0110053112 | Thyroid | PTC | regulation of actin filament organization | 146/5968 | 278/18723 | 5.87e-13 | 2.85e-11 | 146 |
| GO:1902905113 | Thyroid | PTC | positive regulation of supramolecular fiber organization | 114/5968 | 209/18723 | 8.48e-12 | 3.57e-10 | 114 |
| GO:005149526 | Thyroid | PTC | positive regulation of cytoskeleton organization | 121/5968 | 226/18723 | 1.04e-11 | 4.27e-10 | 121 |
| GO:000815426 | Thyroid | PTC | actin polymerization or depolymerization | 117/5968 | 218/18723 | 1.85e-11 | 7.21e-10 | 117 |
| GO:0032271113 | Thyroid | PTC | regulation of protein polymerization | 123/5968 | 233/18723 | 2.45e-11 | 9.38e-10 | 123 |
| GO:0032535112 | Thyroid | PTC | regulation of cellular component size | 181/5968 | 383/18723 | 1.70e-10 | 5.64e-09 | 181 |
| GO:005105218 | Thyroid | PTC | regulation of DNA metabolic process | 171/5968 | 359/18723 | 2.52e-10 | 8.33e-09 | 171 |
| GO:0031334113 | Thyroid | PTC | positive regulation of protein-containing complex assembly | 121/5968 | 237/18723 | 5.70e-10 | 1.81e-08 | 121 |
| GO:2001020112 | Thyroid | PTC | regulation of response to DNA damage stimulus | 113/5968 | 219/18723 | 9.37e-10 | 2.77e-08 | 113 |
| GO:000806423 | Thyroid | PTC | regulation of actin polymerization or depolymerization | 98/5968 | 188/18723 | 6.00e-09 | 1.53e-07 | 98 |
| GO:003004125 | Thyroid | PTC | actin filament polymerization | 99/5968 | 191/18723 | 7.40e-09 | 1.85e-07 | 99 |
| GO:003083220 | Thyroid | PTC | regulation of actin filament length | 98/5968 | 189/18723 | 8.58e-09 | 2.10e-07 | 98 |
| GO:001082124 | Thyroid | PTC | regulation of mitochondrion organization | 78/5968 | 144/18723 | 2.38e-08 | 5.43e-07 | 78 |
| GO:003227327 | Thyroid | PTC | positive regulation of protein polymerization | 75/5968 | 138/18723 | 3.65e-08 | 8.02e-07 | 75 |
| GO:0051017112 | Thyroid | PTC | actin filament bundle assembly | 83/5968 | 157/18723 | 3.73e-08 | 8.18e-07 | 83 |
| GO:0061572112 | Thyroid | PTC | actin filament bundle organization | 84/5968 | 161/18723 | 6.75e-08 | 1.40e-06 | 84 |
| GO:005105420 | Thyroid | PTC | positive regulation of DNA metabolic process | 100/5968 | 201/18723 | 9.18e-08 | 1.84e-06 | 100 |
| GO:003083326 | Thyroid | PTC | regulation of actin filament polymerization | 88/5968 | 172/18723 | 1.07e-07 | 2.11e-06 | 88 |
| GO:00062828 | Thyroid | PTC | regulation of DNA repair | 65/5968 | 130/18723 | 1.25e-05 | 1.36e-04 | 65 |
| GO:000091019 | Thyroid | PTC | cytokinesis | 82/5968 | 173/18723 | 1.37e-05 | 1.47e-04 | 82 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SPIRE1 | SNV | Missense_Mutation | rs753346539 | c.1094N>A | p.Arg365Gln | p.R365Q | Q08AE8 | protein_coding | tolerated(0.25) | benign(0.116) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SPIRE1 | SNV | Missense_Mutation | rs769420628 | c.1912N>G | p.Ile638Val | p.I638V | Q08AE8 | protein_coding | tolerated(1) | benign(0.203) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SPIRE1 | deletion | Frame_Shift_Del | novel | c.2134delN | p.Ile712SerfsTer18 | p.I712Sfs*18 | Q08AE8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SPIRE1 | SNV | Missense_Mutation | novel | c.833N>T | p.Arg278Met | p.R278M | Q08AE8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SPIRE1 | SNV | Missense_Mutation | novel | c.655N>A | p.Ala219Thr | p.A219T | Q08AE8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SPIRE1 | SNV | Missense_Mutation | novel | c.545N>A | p.Gly182Glu | p.G182E | Q08AE8 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SPIRE1 | SNV | Missense_Mutation | novel | c.516N>T | p.Glu172Asp | p.E172D | Q08AE8 | protein_coding | tolerated(0.11) | probably_damaging(0.99) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SPIRE1 | SNV | Missense_Mutation | rs764517052 | c.643A>T | p.Asn215Tyr | p.N215Y | Q08AE8 | protein_coding | deleterious(0.03) | probably_damaging(0.964) | TCGA-VS-A8EJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| SPIRE1 | insertion | Frame_Shift_Ins | novel | c.517_518insCCCTCATCTTT | p.Gly173AlafsTer32 | p.G173Afs*32 | Q08AE8 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| SPIRE1 | SNV | Missense_Mutation | rs754818224 | c.722N>T | p.Ala241Val | p.A241V | Q08AE8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |